肿瘤靶向一直是药物传递系统的一大挑战。为了改善疗效和生物相容性，已经开发了许多纳米技术衍生的药物载体用于癌症治疗。其中，细胞纳米载体的出现引起了广泛关注，它模拟细胞功能，并具有良好的生物相容性。它们还能逃避网状内皮系统的清除，展现出长循环效应。细胞固有的肿瘤迁移和肿瘤归位能力增加了它们作为肿瘤靶向载体的重要性。在本综述中，我们重点讨论了干细胞、免疫细胞、红细胞和细胞膜与纳米载体的结合，使化疗药物能够有效地靶向病变部位并改善药物分布，同时具有低毒性和安全性。此外，我们还讨论了这些纳米颗粒的优缺点以及未来面临的挑战和机遇。尽管解决这些限制的研究仍在进行中，但这种有前途的肿瘤靶向药物传递系统将为癌症提供一个安全有效的平台。© 2023. Controlled Release Society.

Tumor targeting has been a great challenge for drug delivery systems. A number of nanotechnology-derived drug carriers have been developed for cancer treatment to improve efficacy and biocompatibility. Among them, the emergence of cell-nanocarriers has attracted great attention, which simulates cell function and has good biocompatibility. They can also escape the clearance of reticuloendothelial system, showing a long-cycle effect. The inherent tumor migration and tumor homing ability of cells increase their significance as tumor-targeting vectors. In this review, we focus on the combination of stem cells, immune cells, red blood cells, and cell membranes to nanocarriers, which enable chemotherapy agents to efficiently target lesion sites and improve drug distribution while being low toxic and safe. In addition, we discuss the pros and cons of these nanoparticles as well as the challenges and opportunities that lie ahead. Although research to address these limitations is still ongoing, this promising tumor-targeted drug delivery system will provide a safe and effective platform against cancer.© 2023. Controlled Release Society.